Nelfinavir
Protease Inhibitor — ANTIINFECTIVES FOR SYSTEMIC USE
Also known as: nelfinavir mesilate, nelfinavir mesylate, viracept
Data last refreshed: (DrugCentral release 2024-11-01)
Key facts
Nelfinavir is an ofp drug in the Protease Inhibitor class catalogued in DrugCentral. It was first approved by the FDA in 1997. Its mechanism of action is classified as Cytochrome P450 3A Inhibitors and HIV Protease Inhibitors. DrugCentral lists 27 molecular targets, including pol, protease and HIV-1 protease. Recorded indications include Human immunodeficiency virus infection.
- Approval status: ofp (first approved 1997 by the FDA).
- Drug class: Protease Inhibitor.
- Mechanism of action: Cytochrome P450 3A Inhibitors; HIV Protease Inhibitors.
- Molecular targets: pol, protease, HIV-1 protease and HIV-1 protease (27 listed in DrugCentral).
- Indications: Human immunodeficiency virus infection.
- ATC code: J05AE04 (Protease inhibitors).
- Molecular formula: C32H45N3O4S; molecular weight 567.79 g/mol.
Indications & contraindications
Drug–disease relationships curated by DrugCentral (OMOP / SNOMED concepts).
Indications (1)
- Human immunodeficiency virus infection
Contraindications (8)
- Breastfeeding (mother)
- Depressive disorder
- Diabetes mellitus
- Diarrhea
- Disease of liver
- Hemophilia
- Hyperglycemia
- Pregnancy, function
Mechanism & targets
| Mechanism of action (MoA) | Cytochrome P450 3A Inhibitors; HIV Protease Inhibitors |
|---|---|
| Established pharmacologic class | Protease Inhibitor |
Molecular targets (27)
| Target | Gene | Action | Activity |
|---|---|---|---|
| Pol polyprotein | pol | inhibitor | Ki 11.00 |
| Protease | protease | unknown | Ki 10.15 |
| Protease | HIV-1 protease | unknown | Ki 8.68 |
| Protease | HIV-1 protease | unknown | Ki 8.49 |
| Cytochrome P450 3A4 | CYP3A4 | unknown | IC50 5.70 |
| Progesterone receptor | PGR | unknown | Ki 5.24 |
| Mu-type opioid receptor | OPRM1 | unknown | Ki 5.23 |
| D(1A) dopamine receptor | DRD1 | unknown | Ki 5.19 |
| Tyrosine-protein kinase Fyn | FYN | unknown | IC50 5.10 |
| Adenosine receptor A3 | ADORA3 | unknown | Ki 5.08 |
| Sodium-dependent noradrenaline transporter | SLC6A2 | unknown | Ki 5.06 |
| Substance-K receptor | TACR2 | unknown | Ki 5.01 |
| Sodium-dependent dopamine transporter | SLC6A3 | unknown | Ki 4.91 |
| ATP-binding cassette sub-family G member 2 | ABCG2 | unknown | IC50 4.90 |
| Arachidonate 15-lipoxygenase | ALOX15 | unknown | IC50 4.86 |
| Kappa-type opioid receptor | OPRK1 | unknown | Ki 4.84 |
| Mitogen-activated protein kinase 14 | MAPK14 | unknown | IC50 4.74 |
| Multidrug resistance protein 1 | ABCB1 | unknown | IC50 4.70 |
| Thromboxane-A synthase | TBXAS1 | unknown | IC50 4.68 |
| Mitogen-activated protein kinase 3 | MAPK3 | unknown | IC50 4.65 |
Regulatory approvals (1)
| Date | Agency | Marketed as | Applicant | Orphan |
|---|---|---|---|---|
| 1997-03-14 | FDA | — | AGOURON |
ATC classification
| ATC code | Therapeutic hierarchy |
|---|---|
J05AE04 | ANTIINFECTIVES FOR SYSTEMIC USE › ANTIVIRALS FOR SYSTEMIC USE › DIRECT ACTING ANTIVIRALS › Protease inhibitors |
Pharmacogenomics
Drug-label and guideline annotations from PharmGKB and CPIC.
- EMA label: CYP3A4
- FDA label: CYP2C19, CYP3A4, CYP3A5
Reported adverse-event signals
Strongest FDA FAERS disproportionality signals (log-likelihood ratio). A signal is a statistical association in spontaneous reports, not proof that the drug causes the event.
| MedDRA term | LLR |
|---|---|
| Lipodystrophy acquired | 718.4 |
| Exposure during pregnancy | 717.8 |
| Foetal exposure during pregnancy | 576.5 |
| Virologic failure | 553.1 |
| Viral mutation identified | 517.6 |
| Mitochondrial toxicity | 517.0 |
| Progressive external ophthalmoplegia | 471.3 |
| Pathogen resistance | 390.5 |
| Eyelid ptosis | 373.2 |
| Drug resistance | 345.7 |
| Premature baby | 232.8 |
| Caesarean section | 226.1 |
Chemical structure
| Molecular formula | C32H45N3O4S |
|---|---|
| Molecular weight | 567.79 g/mol |
| CAS number | 159989-64-7 |
| InChIKey | QAGYKUNXZHXKMR-HKWSIXNMSA-N |
| PubChem CID | 64143 |
Frequently asked questions
Answers are generated from the structured data on this page, not written by hand.
What is Nelfinavir used for?
DrugCentral lists the following indications for Nelfinavir: Human immunodeficiency virus infection.
How does Nelfinavir work?
Nelfinavir is classified as Cytochrome P450 3A Inhibitors and HIV Protease Inhibitors; its molecular targets in DrugCentral include pol (inhibitor), protease, HIV-1 protease and HIV-1 protease.
When was Nelfinavir first approved?
Nelfinavir was first approved by the FDA in 1997.
What drug class does Nelfinavir belong to?
Nelfinavir is in the Protease Inhibitor class.
What is the chemical formula of Nelfinavir?
Nelfinavir has the molecular formula C32H45N3O4S and a molecular weight of 567.79 g/mol.
Browse: all drugs starting with N · drug guides by category · protein targets A–Z.
Sources
- DrugCentral drug card 1893 — structure, indications, targets, approvals, pharmacologic classes (CC BY-SA 4.0)
- ChEMBL CHEMBL1205 — compound record and bioactivity
- PubChem CID 64143 — chemical identifiers
- DrugBank DB00220 — drug record
- FDA UNII HO3OGH5D7I — substance identity
- DailyMed: FDA labels for Nelfinavir — current prescribing information (label search)
- UniProt P08684 (CYP3A4) — target protein
- UniProt P35372 (OPRM1) — target protein
- UniProt P21728 (DRD1) — target protein
- UniProt P06241 (FYN) — target protein
- UniProt P0DMS8 (ADORA3) — target protein
- UniProt P23975 (SLC6A2) — target protein
- FDA Adverse Event Reporting System (openFDA FAERS) — adverse-event signals, as aggregated by DrugCentral
- PharmGKB / CPIC — pharmacogenomic label annotations
How this page is built: methodology · editorial policy & corrections.
For research and educational use only — not medical advice. This page is compiled automatically from public databases. It is not written or reviewed by a clinician. Do not start, stop or change any treatment based on it; consult a qualified healthcare professional. Spotted an error? See our corrections policy or email hello@molforge.ai.